23 September 2020 : Clinical Research
Gamma Knife Radiosurgery (GKRS) for Patients with Prolactinomas: Long-Term Results From a Single-Center Experience
Yanli Li1AEG, Minyi Huang2BCD, Shunyao Liang2BC, Chao Peng3CDE, Xi Li4BCD, Jiamin Zeng5CD, Yong He2BF, Wangen Li1EF, Yinhui Deng2ADG, Jinxiu Yu2BCE*DOI: 10.12659/MSM.924884
Med Sci Monit 2020; 26:e924884
Table 1 Patient baseline characteristics of pre-GKRS and GKRS parameters.
| Characteristic | Value |
|---|---|
| Male/Female, n (%) | 5/19 (20.8/79.2) |
| Median age, (range), years | 30.5 (18.1–51.1) |
| Median follow-up time, (range), months | 109.3 (23.2–269.3) |
| Median tumor volume, (range), cm | 0.716 (0.019–6.535) |
| Tumor size, n (%) | |
| Microadenoma | 10 (41.7) |
| Macroadenoma | 13 (54.2) |
| Giant adenoma | 1 (4.2) |
| Indication for GKRS | |
| Resistance to DA | 20 (83.3) |
| Drug intolerance | 4 (16.7) |
| Type of DAs | |
| Bromocriptine | 22 (91.7) |
| Cabergoline | 2 (8.3) |
| Suprasellar extension, n (%) | 6 (25) |
| Cavernous sinus invasion, n (%) | 4 (16.7) |
| pre-GKRS | |
| DAs treatment, n (%) | 24 (100) |
| Surgical resection, n (%) | 3 (12.5) |
| Hypopituitarism prior to GKRS, n (%) | 16 (66.7) |
| Gonadotrophin deficiency | 15 (62.5) |
| ACTH deficiency | 1 (4.2) |
| TSH deficiency | 5 (20.8) |
| Visual function, n (%) | |
| Normal | 20 (83.3) |
| Visual dysfunction* | 4 (16.7) |
| Cranial nerve dysfunction of pre-GKRS, n (%) | 0 |
| Median margin dose, (range), Gy | 15 (10.5–23.6) |
| Median maximum dose, (range), Gy | 33.2 (24–66.6) |
| Median isodose level, (range), (%) | 40 (30–60) |
| GKRS – gamma knife radiosurgery; ACTH – adrenocorticotropic hormone; TSH – thyroid-stimulating hormone; DAs – dopamine agonist. * Visual dysfunction consisted of visual field defect and/or visual acuity decrease. | |